Based in Lyon, France, the Technology Research Platform Virnext is a spin-off (EZUS Lyon) of Université Claude Bernard Lyon 1 (UCBL1) and is part of the RESPIVIR research laboratory. Its mission is to foster industrial partnerships and enhance translational research. These collaborations have resulted in a substantial portfolio of patents, technology transfers to industry, the development of several partnership-based initiatives, the implementation of clinical trials, and the creation of start-ups.
With fully-functional BSL-2 and BSL-3 in-house facilities, Virnext expertise extends to the field of respiratory viruses and provides a large panel of technologies, including the production of high-quality, deeply characterized viruses and viral vaccine antigens in egg and cell-based systems and services dedicated to the evaluation of prophylactic and therapeutic candidates of interest by using in vitro (cell lines and reconstituted human airway epithelium) and in vivo models of respiratory virus infections.
Focusing its efforts in R&D and ensuring constantly new technical skills, Virnext proposes a support in the design of protocols and the implementation of preclinical studies, with reactivity and adapted and customized solutions corresponding to customer needs.
Our collaborators
Our scientific team is composed by different experience profiles with multidisciplinary skills. The extensive expertise of our collaborators in virology, molecular and cellular biology, immunology, antiviral therapeutics and viral vaccines development and evaluation, allows Virnext to meet your requests and to carry out your services.
